.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01M_QuinoloneAntibacterials.J01MA23_Delafloxacin.Delafloxacin .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01M_QuinoloneAntibacterials.J01MA23_Delafloxacin.Delafloxacin| name: | Delafloxacin | |
| ATC code: | J01MA23 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 300 | mg |
| volume of distribution: | 35.0 | L |
| clearance: | 9.3 | L/h |
| other parameters in model implementation | ||
Delafloxacin is a fluoroquinolone antibiotic approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and community-acquired bacterial pneumonia (CABP) in adults. It is active against a broad range of Gram-positive and Gram-negative bacteria, including MRSA.
Population pharmacokinetic model for healthy adult subjects and infected patients, both male and female, aged 18–85 years; values represent typical PK after a single 300 mg intravenous infusion or 450 mg oral dose. Oral PK represents fasted state.
Lv, J-X, et al., & Su, Y-W (2024). Pharmacokinetics and pharmacodynamics of intravenous delafloxacin in healthy subjects: model-based dose optimization. Antimicrobial agents and chemotherapy 68(7) e0042824–None. DOI:10.1128/aac.00428-24 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38899925